Advertisement
Canada markets open in 18 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7288
    -0.0010 (-0.13%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • Bitcoin CAD

    86,550.73
    -4,170.53 (-4.60%)
     
  • CMC Crypto 200

    1,349.06
    -33.51 (-2.42%)
     
  • GOLD FUTURES

    2,342.40
    +4.00 (+0.17%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.7210
    +0.0690 (+1.48%)
     
  • NASDAQ futures

    17,385.25
    -279.25 (-1.58%)
     
  • VOLATILITY

    16.87
    +0.90 (+5.64%)
     
  • FTSE

    8,065.22
    +24.84 (+0.31%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6820
    +0.0001 (+0.01%)
     

Sage Therapeutics’ Operational Performance

Sage Therapeutics’ Operational Performance

In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. The company’s revenues are expected to increase to $156.84 million in fiscal 2020. Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Sarepta Therapeutics (SRPT) are expected to have revenues of $13.31 billion, $1.52 billion, and $301.13 million, respectively, in fiscal 2018.